As CLR also facilitates adhesion of head, neck and breast cancer cells to the lymphatic endothelium and thus favor tumor invasiveness (156), NDC-mediated inhibition of CLR may directly impact in the invasiveness of cancer cells. Here, DCLK3 is linked to breast cancer.